Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum.

Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC.

Ann Neurol. 2020 Feb 22. doi: 10.1002/ana.25708. [Epub ahead of print]

PMID:
32086972
2.

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis.

Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, Murphy SP, Mercaldo ND, Zhang L, Zlotoff DA, Reynolds KL, Alvi RM, Banerji D, Liu S, Heinzerling LM, Jones-O'Connor M, Bakar RB, Cohen JV, Kirchberger MC, Sullivan RJ, Gupta D, Mulligan CP, Shah SP, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Lawrence DP, Mahmoudi M, Devereux RB, Forrestal BJ, Mandawat A, Lyon AR, Chen CL, Barac A, Hung J, Thavendiranathan P, Picard MH, Thuny F, Ederhy S, Fradley MG, Neilan TG.

J Am Coll Cardiol. 2020 Feb 11;75(5):467-478. doi: 10.1016/j.jacc.2019.11.049.

PMID:
32029128
3.

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y.

J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4.

PMID:
31800340
4.

The Evolution of Adjuvant Therapy for Melanoma.

Cohen JV, Buchbinder EI.

Curr Oncol Rep. 2019 Nov 25;21(12):106. doi: 10.1007/s11912-019-0858-3. Review.

PMID:
31768772
5.

Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.

Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL.

Oncologist. 2019 Nov 21. pii: theoncologist.2018-0883. doi: 10.1634/theoncologist.2018-0883. [Epub ahead of print] No abstract available.

6.

Neurologic complications of melanoma.

Cohen JV, Wang N, Venur VA, Hadfield MJ, Cahill DP, Oh K, Brastianos PK.

Cancer. 2020 Feb 1;126(3):477-486. doi: 10.1002/cncr.32619. Epub 2019 Nov 14. Review.

PMID:
31725902
7.

Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study.

Chen ST, Molina GE, Lo JA, Durbin S, Cohen JV, Reynolds KL, Kroshinsky D.

J Am Acad Dermatol. 2019 Sep 24. pii: S0190-9622(19)32770-7. doi: 10.1016/j.jaad.2019.09.026. [Epub ahead of print] No abstract available.

PMID:
31560981
8.

Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients.

Johnson DB, Taylor KB, Cohen JV, Ayoubi N, Haugh AM, Wang DY, Schlick BD, Voorhees AL, Gage KL, Fintelmann FJ, Sullivan RJ, Eroglu Z, Abramson RG.

Cancer Immunol Res. 2019 Nov;7(11):1755-1759. doi: 10.1158/2326-6066.CIR-18-0717. Epub 2019 Aug 28.

PMID:
31462410
9.

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.

Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M.

J Immunother Cancer. 2019 Aug 22;7(1):226. doi: 10.1186/s40425-019-0711-0.

10.

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies.

Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC.

Neurology. 2019 Sep 10;93(11):e1093-e1103. doi: 10.1212/WNL.0000000000008091. Epub 2019 Aug 12.

PMID:
31405908
11.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.

Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM.

Nat Med. 2019 Aug;25(8):1243-1250. doi: 10.1038/s41591-019-0523-2. Epub 2019 Jul 22.

12.

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.

Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen JV, Sullivan RJ, Nachtigall L, Tritos N.

Eur J Endocrinol. 2019 Sep;181(3):211-219. doi: 10.1530/EJE-19-0238.

PMID:
31176301
13.

Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.

Cohen JV, Sullivan RJ.

Clin Cancer Res. 2019 Oct 1;25(19):5735-5742. doi: 10.1158/1078-0432.CCR-18-0836. Epub 2019 Apr 16. Review.

PMID:
30992297
14.

Targeting Molecular Pathways in Intracranial Metastatic Disease.

Venur VA, Cohen JV, Brastianos PK.

Front Oncol. 2019 Mar 4;9:99. doi: 10.3389/fonc.2019.00099. eCollection 2019. Review.

15.

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.

Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG.

J Immunother Cancer. 2019 Feb 22;7(1):53. doi: 10.1186/s40425-019-0535-y.

16.

Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.

Bello E, Cohen JV, Mino-Kenudson M, Dougan M.

J Immunother Cancer. 2019 Feb 11;7(1):41. doi: 10.1186/s40425-019-0524-1.

17.

Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal.

Cohen JV, Flaherty KT.

Clin Cancer Res. 2019 Feb 1;25(3):910-911. doi: 10.1158/1078-0432.CCR-18-3296. Epub 2018 Dec 3.

18.

From Puppy to Patient: Translational Oncology.

Cohen JV.

JAMA Intern Med. 2019 Jan 1;179(1):7-8. doi: 10.1001/jamainternmed.2018.5464. No abstract available.

PMID:
30419090
19.

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.

Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ, Sullivan RJ, Schoenfeld SR.

Semin Arthritis Rheum. 2019 Jun;48(6):1127-1132. doi: 10.1016/j.semarthrit.2018.10.012. Epub 2018 Oct 16.

PMID:
30409415
20.

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB.

J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8.

21.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
22.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

23.

Sisu-The Ability to Keep Fighting After Most Would Quit.

Cohen JV.

JAMA Oncol. 2018 Oct 1;4(10):1329. doi: 10.1001/jamaoncol.2018.1571. No abstract available.

PMID:
29902296
24.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG.

J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.

25.

Are we entering the era of combination therapy for melanoma?

Cohen JV, Sullivan RJ.

Melanoma Manag. 2017 Mar;4(1):5-8. doi: 10.2217/mmt-2016-0029. Epub 2017 Mar 1. No abstract available.

26.

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB.

Clin Cancer Res. 2017 Aug 1;23(15):4270-4279. doi: 10.1158/1078-0432.CCR-16-3146. Epub 2017 Feb 21.

27.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.

28.

Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

Curtis SA, Cohen JV, Kluger HM.

Curr Oncol Rep. 2016 Sep;18(9):57. doi: 10.1007/s11912-016-0542-9. Review.

PMID:
27475806
29.

A Patient With Pancytopenia, Intractable Epistaxis, and Metastatic Prostate Cancer: How Correct Diagnosis of Primary Hyperfibrinolysis Helps to Stop the Bleeding.

Jafri MA, Cohen JV, Much MA, Petrylak DP, Podoltsev NA.

Clin Genitourin Cancer. 2016 Oct;14(5):e545-e548. doi: 10.1016/j.clgc.2016.05.002. Epub 2016 May 27. No abstract available.

PMID:
27320762
30.

Systemic Immunotherapy for the Treatment of Brain Metastases.

Cohen JV, Kluger HM.

Front Oncol. 2016 Mar 9;6:49. doi: 10.3389/fonc.2016.00049. eCollection 2016. Review. No abstract available.

31.

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL, Kluger HM.

Cancer Immunol Res. 2016 Mar;4(3):179-82. doi: 10.1158/2326-6066.CIR-15-0160. Epub 2015 Dec 23.

32.

Intralesional Bleomycin for Warts: Patient Satisfaction and Treatment Outcomes.

Kruter L, Saggar V, Akhavan A, Patel P, Umanoff N, Viola KV, Stebbins W, Smith E, Akhavan A, Cohen JV, Cohen SR.

J Cutan Med Surg. 2015 Sep-Oct;19(5):470-6. doi: 10.1177/1203475415576860. Epub 2015 Mar 18.

PMID:
26271964
33.

Terminal Life.

Cohen JV.

JAMA Oncol. 2015 Sep;1(6):731. doi: 10.1001/jamaoncol.2015.1533. No abstract available.

PMID:
26182334
34.

Paradox of hope.

Cohen JV.

J Palliat Med. 2013 Oct;16(10):1307-8. doi: 10.1089/jpm.2013.0060. Epub 2013 Sep 9. No abstract available.

PMID:
24015817
35.

Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.

Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM.

Fam Cancer. 2012 Mar;11(1):69-75. doi: 10.1007/s10689-011-9480-8.

PMID:
21898151
36.

Music lessons.

Cohen JV.

Ann Intern Med. 2011 Aug 2;155(3):207. doi: 10.7326/0003-4819-155-3-201108020-00026. No abstract available.

PMID:
21810721
37.

Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab.

Cohen JV, Capell BC, Kinniry PA, Epstein AL.

J Rheumatol. 2011 Feb;38(2):398-9. doi: 10.3899/jrheum.100641. No abstract available.

PMID:
21285183
38.

Lessons learned as a third-year medical student on a rotation in palliative medicine.

Cohen JV.

J Palliat Med. 2008 Jun;11(5):781-2. doi: 10.1089/jpm.2008.0022. No abstract available.

PMID:
18588413

Supplemental Content

Loading ...
Support Center